In a xenograft orthotopic subcutaneous and peritoneal model of OC in immunocompetent mice, intraperitoneal administration of FSHR-targeted T cells demonstrated significant therapeutic response, even tumor rejection, and an increased survival without on-target, off-tumor toxicity. Here, FSHR is linked to neoplasm.